Liabooks Home|PRISM News
PRISM

#FDA Approval

Total 1 articles

Novo Nordisk Soars 8% as U.S. Greenlights Oral Wegovy, Unlocking Massive New Market
EconomyEN
Novo Nordisk Soars 8% as U.S. Greenlights Oral Wegovy, Unlocking Massive New Market

Novo Nordisk (NVO) stock jumped 8% following FDA approval for the oral pill version of its weight-loss drug Wegovy. The move is expected to significantly broaden patient access and intensify competition with Eli Lilly.